Dr. Larry Kerr

Building Health System Resilience: The Role of Antimicrobials A video series celebrating World Antimicrobial Awareness Week 2021   “Public-private partnerships are one of the invaluable mechanisms for preparedness against global health threats like AMR.” -Dr. Larry Kerr Director of the Office of Pandemics and Emerging Threats within the Office of the United States Department of […]

Dr. Manica Balasegaram

Building Health System Resilience: The Role of Antimicrobials A video series celebrating World Antimicrobial Awareness Week 2021 “New treatments will only be successful if they are available to everyone, including in low- and middle-income countries, and used responsibly and appropriately.” -Dr. Manica Balasegaram Executive Director, Global Antibiotic Research & Development Partnership (GARDP)

Dr. Ramanan Laxminarayan

Building Health System Resilience: The Role of Antimicrobials A video series celebrating World Antimicrobial Awareness Week 2021   “We certainly aren’t where we need to be with respect to fixing the market failures or with having a full pipeline, but we certainly are in a better place than we were just a few years ago…A […]

World Antimicrobial Awareness Week (WAAW) 2021

As part of this year’s World Antimicrobial Awareness Week (WAAW) the AMR Industry Alliance will host a virtual panel session on Supporting the optimal use of antimicrobial medicines through innovation. When? 23 November 2021 at 13:00-14:00 CET / 07:00-08:00 EST. What? This year’s WAAW will take place 18-24 November 2021, with the theme “Spread Awareness, Stop Resistance”. You can read […]

Request for Proposals: Developing a sustainability framework for off-patent antibiotics

The AMR Industry Alliance is currently seeking proposals to support the work of its Access Working Group. The duration of this consultancy is defined for a period of approximately 6 months, starting 22 October 2021 (or as soon as the procurement process is completed) and ending 28 February 2022 when the deliverables have been approved by the AMR Industry Alliance Board. The consultancy will be conducted under the overall guidance of the AMR Industry Alliance Access Working Group Lead and Core Team. The Consultancy will be home-based, from any country.

Request for Proposals: Regulatory Landscape Phase 1

  To view as a PDF, click here. Overview The AMR Industry Alliance is one of the largest private sector coalitions established to provide sustainable solutions to curb antimicrobial resistance (AMR). The AMR Industry Alliance currently includes over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations. Through its members, the AMR Industry Alliance […]

Request for Proposals: Regulatory Landscape Phase 2

  To view as a PDF, click here. Overview   The AMR Industry Alliance is one of the largest private sector coalitions established to provide sustainable solutions to curb antimicrobial resistance (AMR). The AMR Industry Alliance currently includes over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations. Through its members, the AMR Industry […]

Stewardship Prize: Strengthening Stewardship and Appropriate Use in Low- and Middle-Income Countries

About the Stewardship Prize While significant efforts have been initiated across low- and middle-income countries (LMICs) to address AMR stewardship and appropriate use of antibiotics, limited resources exist to expand these activities. Through its Stewardship Prize initiative, the AMR Industry Alliance aims to identify and recognize innovative new approaches to AMR stewardship in LMICs. To […]

AMR life sciences industry 2020 report: Successes and setbacks in fighting superbugs

 AMR Industry Alliance reports breakthroughs in the responsible manufacturing of antibiotics and positive steps to improve how patients access and use antibiotics. But its report also highlights concerning levels of research and development (R&D) investment.   Alliance records US1.6B annual investment (in 2018) in antimicrobial resistance (AMR)-relevant R&D. Concerning shortfall is in late stage R&D investment […]

AMR Industry Alliance Round-Up, Issue No.3, November 2019

Welcome to the third issue of the Alliance Round-Up – written for more than 100 biotech, diagnostic, generic and R&D pharma companies that are members of the AMR Industry Alliance, as well as people interested in collaborating with the Alliance to combat antimicrobial resistance. Through this newsletter, we aim to share news, updates and expert opinions […]